Indian stocks: Visit www.stage2stocks.com →

Caris Life Sciences, Inc.

Stage 2 · Advancing · week 6

As of Oct 22, 2026, Caris Life Sciences is in Stage 2, the uptrend phase, now in week 6 (since Sep 16, 2026). It closed at $31.71, 1.7% below its 52-week high and above its 200-day average, which is rising.

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. More about the company

$31.71
-0.94% today
$9.0B · Mid cap
Market Neutral — Building

Pro read

Pro

Our read

Early entry: still early enough in its move

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is CAI early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2025-06-18 → 2026-10-22
S? 41w
S4 18w
2025-06-182026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 41w → S4 18w → S1 5w → S2 5w current
Total tracked: 70 weeks across 4 stage runs.

CAI among Biotechnology186th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…186CAIStage 2 · wk 655+0.2%
vs 52W High
-1.7%
$14.55 lo$32.27 hi
Near 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 6
1w13w26w
Week 6, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
48.4%
200 DMA: $21.37 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.51x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
Short-term trend rising gently
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+0.2%
3M
+104.3%
6M
+60.2%
YTD
+17.5%
1Y
+0.6%
Scan Membership
Not in any current scan.
Recent Stage Timeline
2026-10-22S2
Wk 6 · Vol 0.51x
2026-10-21S2
Wk 6 · Vol 0.41x
2026-10-20S2
Wk 5 · Vol 0.72x
2026-10-19S2
Wk 5 · Vol 0.42x
2026-10-16S2
Wk 5 · Vol 0.52x
2026-10-15S2
Wk 5 · Vol 0.67x
2026-10-14S2
Wk 5 · Vol 0.82x
2026-10-13S2
Wk 4 · Vol 0.66x
2026-10-12S2
Wk 4 · Vol 0.94x
2026-10-09S2
Wk 4 · Vol 0.95x
2026-10-08S2
Wk 4 · Vol 0.72x
2026-10-07S2
Wk 4 · Vol 0.92x
Moving averages & range
50 DMA
$27.75
200 DMA
$21.37
52W High
$32.27
52W Low
$14.55
5D Low
$30.56
Resistance levels (recent highs)
20d High
$32.01
60d High
$32.27
120d High
$32.27
250d High
$32.27
Next resistance
+0.9%
to 20d High
P/E (TTM)
18.8
Forward 85.3
ROE
+20.1%
Profit margin +10.6%
Dividend Yield
0.00%
P/B 15.1

Caris Life Sciences: quick answers

What stage is Caris Life Sciences in?

As of Oct 22, 2026, Caris Life Sciences (CAI) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 16, 2026 and is in week 6. What the four stages mean

Is Caris Life Sciences in an uptrend?

Yes. Caris Life Sciences is in a Stage 2 uptrend. It trades 48.4% above its 200-day average, which is rising.

How far is Caris Life Sciences from its 52-week high?

Caris Life Sciences closed at $31.71 on Oct 22, 2026, 1.7% below its 52-week high of $32.27. Its 52-week low is $14.55.

How has Caris Life Sciences performed over the past year?

As of Oct 22, 2026, Caris Life Sciences is up 0.6% over the past year and up 17.5% so far in 2026.

Which sector and industry is Caris Life Sciences in?

Caris Life Sciences is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.